FDA Approves Vonjo (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

SEATTLE, Feb. 28, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved Vonjo (pacritinib) for the treatment of adults with i

Latest News NDA News 175
Read All

FDA Approves Releuko (filgrastim-ayow), a Biosimilar to Neupogen

February 28, 2022 -- The United States (U.S.) Food and Drug Administration (FDA) has approved Releuko (filgrastim-ayow), a biosimilar to Neupogen (filgrastim). The FDA approval was based on a review o

Latest News NDA News 175
Read All

FDA Approves Norliqva (amlodipine) Oral Solution for Hypertension and Coronary Artery Disease

February 28, 2022 -- The U.S. Food and Drug Administration has approved Norliqva (amlodipine) oral solution for the treatment of: Hypertension in adults and children 6 years and older, to lower blood

Latest News NDA News 177
Read All

FDA Approves NephroScan (Kit for the Preparation of Technetium Tc 99m Succimer Injection) for Radiodiagnostic Imaging

LONDON, UK, 21 February 2022 -- Theragnostics announces that NephroScan, its radiodiagnostic imaging drug used as an aid for the evaluation of renal parenchymal disorders in adult and pediatric patien

Latest News NDA News 203
Read All

FDA Approves Pyrukynd (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, toda

Latest News NDA News 329
Read All

FDA Approves Enjaymo (sutimlimab-jome) for Use in Patients with Cold Agglutinin Disease

Paris, February 4, 2022. -- The U.S. Food and Drug Administration (FDA) has approved Enjaymo™ (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold

Latest News NDA News 176
Read All

FDA Approves Fleqsuvy (baclofen oral suspension) for the Treatment of Spasticity

WOBURN, MA, February 7, 2022 -- Azurity Pharmaceuticals, Inc., a private specialty pharmaceutical company, focused on developing innovative products to meet the unique needs of patients with underserv

Latest News NDA News 207
Read All

Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax

Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose Spikevax has received approval by regulators in more than 70 countrie

Latest News NDA News 216
Read All

FDA Approves Vabysmo (faricimab-svoa) for the Treatment of Neovascular (Wet) Age-Related Macular Degeneration and Diabetic Macular Edema

South San Francisco, CA -- January 28, 2022 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysm

Latest News NDA News 193
Read All

FDA Approves Kimmtrak (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Kimmtrak is the first and only FDA approved therapy for the treatment of unresectable or metastatic uveal melanoma (mUM) Kimmtrak is the first T cell receptor (TCR) therapeutic to receive regulatory a

Latest News NDA News 431
Read All

FDA Approves Ryaltris (mometasone and olopatadine) Nasal Spray for Seasonal Allergic Rhinitis

Mumbai (Maharashtra) [India], January 14, 2022 (ANI/PRNewswire) -- Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company announced that its fully owned subsidiary

Latest News NDA News 357
Read All

FDA Approves Cibinqo (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis

NEW YORK--(BUSINESS WIRE) January 14, 2022 -- Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved Cibinqo® (abrocitinib), an oral, once-da

Latest News NDA News 564
Read All
News
- CLINIEXPERT -
Int'l Clinical Service Expert

We are the leader
Because of our professionism